Reddit Posts
CytoDyn Stock: Repositioning And Refocusing With New Leadership (OTCMKTS:CYDY)
Just my .02...here's what I'm playing this week.
$CYDY Up 200+% past 30 days and climbing into Friday. Closing at highs.
$CYDY Making A Move 200+% last 30 days and climbing going into Friday. Zero short shares available.
$CYDY making the move 08/03/2022 - 142% increase w/out a squeeze "yet"
$CYDY making the move 08/03/2022 - 142% increase w/out a squeeze "yet"
$CYDY Up 100% past month and 25% past week and still climbing
The next biotech rocket: June 25 2022 - Cytodyn will report its NASH results
Biotech CYDY has solid research out, stock is undervalued in terms of potential. Lots of important catalysts upcoming
CYDY - Save people’s lives from big pharma’s greed
$RGMP Skyrockets 600% After Entering Into Agreements with $CYDY and SevenScore Pharmaceuticals to Commercialize HIV Treatment
Cydy 2x or 3x with 2 news events over 20 days.
Cydy 2x maybe 3x on two events 10 and 20 days from now. Minimal downside
Cydy could be 3x to 4x in 20 days with 2 news events.
EXPOSED: US Gov Censorship FAIL Of YouTube Video about Leronlimab monoclonal antibody $CYDY
Mentions
CYDY financials don’t look sexy but I would recommend people dig into the scientific research of Leronlimab . The drug has major potential for cancer, inflammation, and hiv.
CYDY’s current senior VP was hired by Bill and Melinda Gates Foundation to lead their global HIV program. Also gave about $1mill for research of Leronlimab.
In at 0.56. RVPH can't run like BTAI did because there's no exact date for the FDA meeting. Speculation aside, short-term upside and downside are about even. But the drug itself (brilaroxazine) threatens the market share of *all* current anti-psychotics. Along with GPS (SLS), INT230-6 (INTS), and leronlimab (CYDY), it's one of the most clinically promising drugs in biotech right now. There's some better stuff at the proof-of-concept stage (PYXS) or Phase 1 (LNAI) but they're essentially gambles. If you've got the risk appetite to choose biotech at all, you're okay holding RVPH for years.
CYDY - Been holding for years.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
is quietly positioning itself for a major comeback in the biotech space. With a renewed leadership team, a streamlined focus on regulatory compliance, and promising developments around its flagship drug, leronlimab, the company is regaining momentum. Recent steps toward resolving past clinical and legal hurdles signal a turning point, as CYDY works to unlock the full potential of its novel CCR5 antagonist, a therapy with broad implications across HIV, cancer, NASH, and other inflammatory indications. As progress continues and regulatory clarity improves, CYDY could be setting the stage for significant upside, offering early investors a rare opportunity in a deeply discounted biotech with transformative therapeutic potential.
CYDY. It's going to be life changing.
Ill have to look into CYDY a bit more once I close my current positions. My portfolio is currently tied up in 5 positions right, but i'll probably close 3 of them end of this month, then I'll able to invest in other plays Is this a short term or long term hold for you?
Best Results from CYDY (Leronlimab) Trials – Summary HIV (Combination Therapy & Monotherapy) 1) Achieved primary endpoint in Phase 3 trial for treatment-experienced patients. 2) Some patients on monotherapy maintained viral suppression for years. COVID-19 (Severe/Critical Cases) 1) Phase 3 data showed reduced mortality and faster hospital discharge in critical patients vs. placebo. NASH/MASH (Liver Disease) 1) Phase 2 (open-label): 50% of patients showed ≥80ms reduction in cT1, a key marker of liver disease severity. Preclinical data showed reversal of fibrosis and liver fat reduction. Metastatic Triple-Negative Breast Cancer (mTNBC) 1) In small subgroup, 15/17 patients on ≥525 mg dose showed increased PD-L1 expression (potential synergy with immunotherapy). 2) Some long-term survivors (up to 4 years with no evidence of disease). Metastatic Colorectal Cancer (MSS, CCR5+) 1) FDA cleared Phase 2 trial design combining leronlimab with TAS-102 + bevacizumab. Trial to assess ORR and safety. Promising. Something for the longs to feel hopeful in seeing.
CYDY have way better results. Check for yourself because I’m mot sound anyone’s DD
CYDY is positioned for success, there’s no doubt about it. They are currently conducting combination trials, which demonstrate both clinical progress and strategic foresight. Coupled with solid financial backing and strong support from the scientific community, their outlook is promising. Additionally, their recent S-3 filing signals they have secured flexible capital resources to sustain development and operations. With these critical elements in place, CYDY is well equipped to advance its pipeline and deliver meaningful results.
For DD. Check the link below. It’s the same as $CYDY but that’s the community page https://www.reddit.com/r/Livimmune/s/0sIFDbiuHV
it's not a chemo drug. it's a ccr5 blocker. The science section is pretty revealing. Our Science :: CytoDyn Inc. (CYDY) [https://share.google/vslBmIYrj8UFzqHTv](https://share.google/vslBmIYrj8UFzqHTv) Imagine the results if it successfully induces pd-l1 in a second sol8d tumor type.
My conviction hasn’t wavered in $CYDY. I truly believe in this investment, and I wouldn’t be surprised if one morning we wake up to see the share price breaking past $1 and running from there.
APLT is my move, got in at 0.62 it's at 0.93 right now Hit big on Adap this week too and cashed most out at 101% but it's still looking like a short term play in the future Hoping CYDY hits tomorrow too I'm in at 0.26
CYDY. Key results & Findings Highlight “for the NCT03902522” posted today; 1) Most patients achieved plasma HIV-1 RNA levels less than 50 copies/mL after 24 weeks, indicating viral suppression in a treatment-experienced population. 2) Leronlimab was generally well tolerated, and no drug-related serious adverse events were reported. 3) Adverse events were predominantly mild, with no significant safety concerns apparent After 1 week, 64% of leronlimab recipients achieved ≥0.5 log₁₀ reduction in HIV-1 RNA (versus 23% for placebo; intent-to-treat analysis) After 24 weeks of extension with leronlimab plus optimized background therapy, most participants maintained plasma HIV-1 RNA levels below 50 copies/mL, suggesting robust long-term viral control Leronlimab was well-tolerated, with the majority of adverse events being mild and no drug-related serious adverse events Compared to current HIV drugs, CYDY’s leronlimab shows several notable efficacy and safety advantages, especially in heavily treatment-experienced patients with multi-drug resistant HIV. Key points of comparison include; Efficacy: In a phase 3 pivotal trial, leronlimab combined with standard antiretroviral therapy achieved viral suppression (<50 copies/mL) in about 81% of heavily treatment-experienced patients, significantly higher than the approximately 43-45% viral suppression rates seen with some recently approved drugs in this difficult-to-treat population. In a phase 2b/3 trial, leronlimab monotherapy maintained viral suppression for several years in some patients, a rare outcome for monotherapy in HIV treatment. Mechanism: Leronlimab is a monoclonal antibody blocking the CCR5 receptor, a co-receptor HIV uses to enter immune cells. This contrasts with most current antiretroviral drugs, which target viral enzymes. This unique mechanism allows leronlimab to remain effective even when resistance has developed against other drug classes. Resistance and Safety: Leronlimab retains full activity despite extensive resistance to the four main antiviral drug classes, and its efficacy is not compromised by exposure to maraviroc, another CCR5 antagonist. It also has a favorable safety profile with lower toxicity, less drug-drug interactions, and fewer serious adverse events reported. It is administered once weekly via subcutaneous injection compared to daily oral dosing for most ART drugs. Convenience and Long-Term Benefits: The less frequent dosing of leronlimab offers greater convenience and potentially better adherence. It also shows promise in protecting healthy cells from HIV entry and preventing transmission. In summary, leronlimab demonstrates superior efficacy in multi-drug resistant HIV cases, a novel entry-inhibition mechanism, improved safety, and more convenient dosing compared to many current HIV drugs, positioning it as a valuable option for patients with limited treatments. However, leronlimab is still investigational and undergoing regulatory review for broader use
CYDY… truly paradigm shifting bio pharma opportunity. thank me later.
OTCQB Venture Market CYDY 50k in https://preview.redd.it/gq4yo5rm70of1.jpeg?width=1320&format=pjpg&auto=webp&s=b83ef88085a498273e2b2a2345b31aa2f5efd639
Just check their website or google mTNBC CYDY results. You may also go to r/Livimmune. Many factual posts supported by articles. A P value of 0.001 for mTNBC, same for HIV, COVID and other indications. Trust your own DD, I wouldn’t post this if I didn’t believe in it myself. GL
CYDY is a bad investment.
I didnt do a good job with my response, but what I was trying to say is CYDY is solid in the science etc…I own a very large investment, I unfortunately got caught up in the hype early, and bad management so to speak but the have righted the ship and close to some big things, and possibly partnership announcement(s) soon…..I probably no more than you my friend, even the stammers about “enchiladas” etc…Nader got me sooo hype, but now Dr. J will bring us home….
About you hinting that CYDY is a bad investment. Do your thing and I’ll do mine! GL
You can keep your own ideas to yourself! Let’s see who will be laughing in a few months. You are really clueless about CYDY and I guarantee it
I own a lot of CYDY u/Livimmune shares but I’m not worried one bit
Well-you bought at the wrong time when it comes to CYDY….you bought the hype, but now they are close to exploding and sitting at .30…..you could have averaged down my friend. The science is sold as a rock. It will happen-soooon
CYDY— Cytodyn is where I am investing.
CYDY Cytodyn. they’re running multiple phase 2 studies. The drug went through a clinical hold and FDA found a drug to be totally safe. They went through some road bumps with a bad CEO multiple years back. Got incredible survival rates for triple negative breast cancer patients. Nothing else like it. Easy 25 times return over the next two years maybe earlier.
Amen on that one I'm in also! Another sleeping giant is CYDY once they gain partnership (very soon) along with FDA approval on their cancer drug that's been PROVEN to reverse/remove breast cancer, this stock could hit 3 digits in the next 5 years
CYDY, RTX, MP, OUST, QBTS, LWLG, AB...this is what I hold
$CYDY Amazing breast cancer results released yesterday at ESMO Breast CANCER CONFERENCE in Germany. 5 women alive 52 months later, 4 with no existing disease, 5th is stable. This is unheard of especially considering sample size was only 29 of the sickest women who failed multiple treatments prior. CHeck out sub LIVIMMUNE
CYDY kicking ass. Big announcement at ESMO cancer conference next week.
Buy CYDY now if you want to recoup your losses.
Check out CYDY if you want to get in early in very early on a promising safe drug that cures HIV and mTNBC
Check out CYDY. Drug cures mTNBC and hiv . Will be running soon
Your post with title "CYDY bio tech" has been removed from r/pennystocks because it is too short. Posts must have at least 50 characters to ensure meaningful discussions. *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/pennystocks) if you have any questions or concerns.*
Check out CYDY. Will be a runner
CYDY is trading OTC. Fuck outta here!
Better add CYDY. You'll thank me later
You need to look at CYDY it has a lot of upcoming news that can make there stock skyrocket
$CYDY updated Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
CYDY updated Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
$CYDY updated Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials December 2024 Letter to Shareholders
Try CYDY: Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
Try looking into CYDY: Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
CYDY Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
Try CYDY Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
Try CYDY Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
CYDY updated Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
OTC company CYDY has a potential platform drug and has gotten through a long rough patch with old management. They have a MAB that works and blocks CCR5 Do your own DD. I have been in for years and still hold.
I’m big on CYDY Cytodyn. At 0.11/share . Now connected to Bill and Melina Gates foundation. Money for research coming in most likely. Their Vice President just announced yesterday that he will be leading BMGF global HIV program. He’s also remaining at CYDY, which could have a cure for HIV and other indications. It should fly on Monday.
My experience with CYDY compels me to tell you no
CYDY but it looks promising now. Partnership announcement and trial results.
CYDY: biotechnology wonder drug will have approvals next year. They’ve had a rough history with FDA and incompetent CEO, but the team in place now is impeccable. This will be a platform drug with many indications. Just get a few thousand shares and forget about it till next year.
You guys are seriously missing $CYDY
Any insights on why $CYDY is moving up?
Why biopharma? There are a lot of wannabe's in this sector and a lot of failures (many of those with huge jumps before collapsing, it must be noted) but the ones who come from nowhere and succeed are moonshots. DD and more DD and more DD is highly recommended to sort the grain from the chaff. Why CYDY? Once viewed as a scam by FDA due to sketchy corporate types the company is under new management and has an actual contender with Leronlimab. The SP is up 50%-ish from the bottom since early May. Worth a look. Remember DD, DD, DD.
If your timeline is longer than a week you might be wanting to view biopharma's. CYDY is my play there for now.
You'll also want to watch Cytodyn CYDY with their molecule Leronlimab. Company has gone through challenges, but fda is now working to structure trial protocols. Name change at some point to Livimmune. Inflammation affects nearly all diseases, this drug will be one to own. r/Livimmune
Biotech: CYDY ticker. Revolutionary molecule that blocks CCR5 cell signals that promote disease, like cancer, HIV, and potentially 80+ indications resulting from immune deficiencies. Don't miss out.
Solid management, stable dividend: EPD Potential 50-bagger in next 12-24 months: CYDY Do your own due diligence.
CYDY will fly tomorrow. Clinical hold lifted. Hoping for a big short squeeze tomorrow.
CYDY, conical hold will be lifted soon. The stock will go anywhere from 10 times to 40 times in the next year.
So I'm heavily invested in CYDY. And NWBO. I BELIEVE IN THE SCIENCE. IN BOTH COMPANY'S!!
CYDY is the best risk to reward ratio stock out there. They had fraud but their product is solid they are just waiting for the FDA to lift the hold. They now have New Management and are going to get involved in the cancer space with a drug that actually works. This is one of those that's going to go from 30 cents to $200 you can Bank on it.
See what happens when you invest in an OTC biotech stock. Talk about blatant manipulation. $CYDY
Hey /u/Independent_Fact_780 - I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: CYDY. We don't allow discussion of low market cap (less than 500mm) tickers to prevent pump & dump spam and scammers.
Hey /u/Maximum_Stock_4587 - I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: NAKD TRNX CYDY. We don't allow discussion of low market cap (less than 500mm) tickers to prevent pump & dump spam and scammers.
TRKA and CYDY LONG. RUMORS OF lifting the hold on CYDY soon not fact..